Press Releases<< Back
CareDx Presents Cell-Free DNA Biomarker Results in Heart and Kidney Transplant Recipients at the World Transplant Congress
In his oral abstract, Dr.
"These results represent just the tip of the iceberg of data we expect to emanate from existing
AlloMap Molecular Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. AlloMap is performed in the
For more information, please visit: www.CareDxInc.com.
CareDx, Inc. Bradley P. SherrillSenior Director, Marketing Tel: 415-287-2397 bsherrill@CareDxInc.com
News Provided by Acquire Media